Back to search

Article

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024

2024-06-05

Abstract excerpt

<h4>Background</h4> Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as “JN lineages”), emerged in late 2023 and exhibited substantial genomic divergence from co-circulating XBB lineages. <h4>Methods</h4> We analyzed patients hospi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7479f920-f487-50cb-bf78-d6c3d41f7e32
DOI
10.1101/2024.06.04.24308470
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024DOI 10.1101/2024.06.04.24308470
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024Semantic proximity
Effectiveness of 2024–2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes — IVY Network, 26 Hospitals, September 1, 2024–April 30, 2025Semantic proximity
XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage VariantsSemantic proximity
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineagesSemantic proximity
Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periodsSemantic proximity
Effectiveness of XBB.1.5 Vaccines Against Omicron SubvariantsSemantic proximity
Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineageSemantic proximity
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudySemantic proximity
Comparative COVID-19 Vaccines Effectiveness in Preventing Infections, Hospitalizations, and Deaths with SARS-CoV-2 BA.5 and Ba.2 Omicron Lineages: A Case-Case and Cohort Study Using Electronic Health Records in PortugalSemantic proximity
Increased vaccine sensitivity of an emerging SARS-CoV-2 variantSemantic proximity
Increased vaccine sensitivity of an emerging SARS-CoV-2 variantSemantic proximity
Select a neighboring publication to make it the new centre.